Jiafu Wang

List of Publications by Year in Descending Order

39 papers	1,168 citations	16 h-index	34 g-index
41 ext. papers	1,402 ext. citations	5.1 avg, IF	4.24 L-index

#	Paper	IF	Citations
39	IL-20 promotes cutaneous inflammation and peripheral itch sensation in atopic dermatitis.. *FASEB Journal*, **2022**, 36, e22334	0.9	0
38	Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis. *Frontiers in Immunology*, **2021**, 12, 696784	8.4	11
37	Novel insights into the TRPV3-mediated itch in atopic dermatitis. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1110-1114.e5	11.5	9
36	Selective Expression of a SNARE-Cleaving Protease in Peripheral Sensory Neurons Attenuates Pain-Related Gene Transcription and Neuropeptide Release. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
35	Innate immune regulates cutaneous sensory IL-13 receptor alpha 2 to promote atopic dermatitis. *Brain, Behavior, and Immunity*, **2021**, 98, 28-39	16.6	4
34	Interventions in the B-type natriuretic peptide signalling pathway as a means of controlling chronic itch. *British Journal of Pharmacology*, **2020**, 177, 1025-1040	8.6	9
33	Role of SNAREs in Atopic Dermatitis-Related Cytokine Secretion and Skin-Nerve Communication. *Journal of Investigative Dermatology*, **2019**, 139, 2324-2333	4.3	8
32	New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators. *International Journal of Molecular Sciences*, **2019**, 21,	6.3	8
31	New mechanism underlying IL-31-induced atopic dermatitis. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1677-1689.e8	11.5	73
30	A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNF‐induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons. *Neuropharmacology*, **2018**, 138, 257-266	5.5	12
29	Conjugate of an IgG Binding Domain with Botulinum Neurotoxin A Lacking the Acceptor Moiety Targets Its SNARE Protease into TrkA-Expressing Cells When Coupled to Anti-TrkA IgG or Fc-NGF. *Bioconjugate Chemistry*, **2017**, 28, 1684-1692	6.3	5
28	A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain. *Neuropharmacology*, **2017**, 118, 223-232	5.5	15
27	Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain. *Scientific Reports*, **2017**, 7, 44474	4.9	5
26	TNF‐induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion. *Scientific Reports*, **2016**, 6, 21226	4.9	59
25	Role of SNARE proteins in tumourigenesis and their potential as targets for novel anti-cancer therapeutics. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2015**, 1856, 1-12	11.2	32
24	Engineering of botulinum neurotoxins as novel therapeutic tools **2015**, 995-1015		2
23	Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediator. *Biochemical Journal*, **2014**, 462, 247-56	3.8	13

22	Fusion of Golgi-derived vesicles mediated by SNAP-25 is essential for sympathetic neuron outgrowth but relatively insensitive to botulinum neurotoxins in vitro. *FEBS Journal*, **2014**, 281, 3243-60	5.7	3
21	Selective cleavage of SNAREs in sensory neurons unveils protein complexes mediating peptide exocytosis triggered by different stimuli. *Molecular Neurobiology*, **2014**, 50, 574-88	6.2	14
20	SNAP-23 and VAMP-3 contribute to the release of IL-6 and TNF from a human synovial sarcoma cell line. *FEBS Journal*, **2014**, 281, 750-65	5.7	15
19	Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons. *FASEB Journal*, **2013**, 27, 3167-80	0.9	16
18	Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25. *Neuropharmacology*, **2013**, 70, 287-95	5.5	14
17	Pharmacological characteristics of Kv1.1- and Kv1.2-containing channels are influenced by the stoichiometry and positioning of their subunits. *Biochemical Journal*, **2013**, 454, 101-8	3.8	14
16	Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. *FEBS Journal*, **2012**, 279, 2555-67	5.7	27
15	Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. *Biochemical Journal*, **2012**, 441, 443-52	3.8	47
14	Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. *Biochemical Journal*, **2012**, 444, 59-67	3.8	33
13	Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. *FASEB Journal*, **2012**, 26, 5035-48	0.9	31
12	Position-dependent attenuation by Kv1.6 of N-type inactivation of Kv1.4-containing channels. *Biochemical Journal*, **2011**, 438, 389-96	3.8	6
11	Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. *FEBS Journal*, **2011**, 278, 4454-66	5.7	35
10	A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. *Journal of Biological Chemistry*, **2011**, 286, 6375-85	5.4	72
9	Arrangement of Kv1 alpha subunits dictates sensitivity to tetraethylammonium. *Journal of General Physiology*, **2010**, 136, 273-82	3.4	20
8	Multiple Steps in the Blockade of Exocytosis by Botulinum Neurotoxins **2009**, 1-14.e1		0
7	Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. *Journal of Neuroscience*, **2009**, 29, 4981-92	6.6	168
6	Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. *Current Opinion in Pharmacology*, **2009**, 9, 326-35	5.1	65
5	Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. *Journal of Biological Chemistry*, **2008**, 283, 16993-7002	5.4	86

4	Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. *Journal of Cell Science*, **2007**, 120, 2864-74	5.3	194
3	Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 320, 410-8	4.7	28
2	Construction of cytopathic PK-15 cell model of classical swine fever virus. *Science Bulletin*, **2003**, 48, 887-891	1.6	6
1	Construction of cDNA library, nucleotide sequence and analysis of entire genome of classical swine fever virus strain Shimen. *Science Bulletin*, **2000**, 45, 367-369		2